Module	**Big Active Molecules**
Code	MSLS_V3_2
Degree Program	Master of Science in Life Sciences (MSLS)
ECTS Credits	4
Workload	Total 120 h: Contact 60 h; Self-study 60 h
Module Coordinator	**Name** Prof. Dr. Sabina Gerber **Phone** +41 (0)58 934 54 28 **Email** sabina.gerber@zhaw.ch **Address** ZHAW Zurich University of Applied Sciences Life Sciences and Facility Management Campus Reidbach PO Box CH-8820 Wädenswil
Lecturers	• Prof. Dr. Sabina Gerber
Entry Requirements	• Solid knowledge of biochemistry and analytical chemistry • Solid knowledge of protein structure and function • Basic knowledge of protein purification • Basic knowledge in molecular biology • Basic knowledge in cell culture technology
Learning Outcomes and Competences	After completing the module students will be able to • understand the use of recombinant proteins as therapeutics • understand the structure and function of monoclonal antibodies • use of bioinformatic tools • understand and be able to apply methods of downstream processing • understand and be able to apply in-process control and quality control methods • understand and be able to apply methods of molecular biology and cell culture technology
Module Content	Topics of the module are Big Active Molecules - in particular proteins - in contrast to Small Active Molecules, organic molecules of low molecular mass. The main focus will be on recombinant antibodies which are the most important molecules in pipeline of the pharmaceutical industry. The structure and function of antibodies and the amazing way evolution has created a system to produce billions of different antibodies in an organism by genetic recombination will be discussed. The basis for the specific antigen recognition of these billions of antibodies by the three-dimensional arrangement of the hypervariable CDR regions will be explained. The understanding of state-of-the-art technologies to select monoclonal antibodies (mAb)

	as therapeutic molecules such as phage display and transgenic mouse strains expressing human antibodies will be followed by the introduction of the diverse formats of engineered antigen binders. These encompass not only antibodies and the different antibody fragments but also protein scaffolds e.g. DARPins. The biological activity of most proteins depends on posttranslational modifications. The influence of glycosylation on the activity of erythropoietin and of mAb will discussed together with the methods used for analysis. A practical course **"Downstream processing and analytics"** will be attended including a downstream process of a marketed mAb with processes reflecting large scale pharmaceutical industry manufacturing and is performed in small scale employing column chromatography. The different process steps will be monitored by in-process controls. The final product, corresponding to the active pharmaceutical ingredient, will be analyzed with the same methods as in the pharmaceutical quality control of a drug substance (analytics of target molecule and impurities such as host cell proteins, host cell DNA etc.). A second part of the practical work includes different projects regarding bioanalytics of monoclonal antibodies.
Teaching / Learning Methods	• Lectures with exercises • To supplement the contents of the lecture, reading of relevant scientific literature in self-study mode and discussion thereof • Practical course with lectures allowing close integration of practical and theoretical aspects • Troubleshooting and critical discussion of results • Self-dependent practical project including planning, performance and analysis of results • Presentation of project results
Assessment of Learning Outcome	• Written examination (50 %, Recombinant proteins as therapeutics) • Oral presentation of project (50 %, "Downstream processing and analytics".)
Bibliography	Selected original papers and book-chapters
Language	German / English
Comments	Attendance in the laboratory course is a strict requirement to complete the module
Last Update	23.08.2024